Clinical Trials

    Capivasertib + CDK4/?6i + Fulvestrant for Advanced/?Metastatic HR+/?HER2- Breast Cancer (CAPItello-292) (CAPItello-292)

    Investigator: Kai Sun

    Study Coordinator: Kelsey Banaglorioso

    Status: Open Not Enrolling

    ClinicalTrials.gov Number: NCT04862663

    Phone: 346.238.5740

    Protocol Number: PRO00037808

    Description


    A Phase Ib/III Open-label, Randomised Study of Capivasertib plus CDK4/6 Inhibitors and Fulvestrant versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer (CAPItello-292)